Pacific Edge Placement Upsized To NZ$16 Million
Pacific Edge today announces it has successfully raised NZ$16 million of new equity in a placement of new ordinary shares (Placement) — NZ$1 million more than it sought — after Directors resolved to accept over subscriptions.2*
The Placement, which was well supported by existing shareholders, was completed on Friday 30 May 2025 and is subject to shareholder approval.3* It was priced at NZ$0.10 cents per share, a premium to the 20-day volume average weighted price (VWAP) prior to the announcement of the company's planned ~NZ$20 million equity issue.
Pacific Edge is now targeting the opening of a NZ$5 million offer to eligible retail investors by way of a Share Purchase Plan (SPP) at the same NZ$0.10 cents per share offer price in July or early August 2025 (with the ability to accept oversubscriptions).4 A shareholder meeting to approve the Placement is planned for late July or early August 2025.
The Placement and the planned SPP are aimed at ensuring Pacific Edge has additional resources and capacity to capitalize on its recent clinical and commercial milestones, grow in non-Medicare channels and regain Medicare coverage of its tests. Medicare coverage of the company's tests ceased after the 'Genetic testing for Oncology; Specific Tests' (L39365) Local Coverage Determination became effective on 24 April 2025.
Chairman Chris Gallaher said: 'We are delighted with the investor support we have received. The inclusion of Cxbladder in the American Urological Association's (AUA) new microhematuria guideline in February 2025 is significant and has allowed the company to view the non-coverage determination differently. We are leveraging the important AUA guideline to build on the commercial momentum we have already established, including our plans to regain Medicare coverage.'
Pacific Edge Chief Executive Dr Peter Meintjes said: 'The robust evidence emerging from our clinical evidence program is shifting clinical sentiment towards the broader adoption of our tests in the US and further afield and represents a significant opportunity in addition to Medicare re-coverage. We are delighted with the strong support we have received from investors to continue to pursue our plans, and we are looking forward to making the same offer to the remainder of our shareholders via the SPP.'
Pacific Edge is advised on the equity raise by Cameron Partners (investment banking advisers), Harmos Horton Lusk (legal advisers) and The Project (investor relations and communications advisers).
For further information on the detail and timetable of the equity raising please refer to the announcement and presentation dated Thursday 29 May 2025 and released by NZX and ASX on Friday 30 May 2025.
Footnote:
1* PEB has released the information contained in this update to the NZX and ASX as it regards it to be material, as defined in the NZX Listing Rules and Section 231 of the FMC Act.
2* Shareholder approval is required to settle the Placement (i.e., for payment for, and allotment of, the new shares offered under the Placement) given the Placement exceeds Pacific Edge's placement capacity (15% of Pacific Edge's current shares on issue) and due to Related Party participation. The Placement is also conditional on all necessary regulatory approvals. In this regard, the company intends to seek a waiver from NZX Listing Rule 4.19.1 to permit the allotment of shares under the Placement after shareholder approval is obtained. The Placement offer closed on 30 May 2025 for the purposes of clause 21(1)(b)(ii) of Schedule 8 to the Financial Markets Conduct Regulations 2014.
3* See footnote 1.
4* No offer of new shares is made under the SPP unless and until Pacific Edge sends the SPP offer document to shareholders. No money is currently being sought, and new shares cannot currently be applied for or acquired, under the SPP.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Otago Daily Times
21 hours ago
- Otago Daily Times
Still as good as gold after 50th donation
Terry Taylor enjoys the act of giving, but yesterday was a special occasion. The Dunedin medical laboratory scientist gave plasma for the 50th time, and decided to meet the person his "liquid gold" goes to. "It's actually painless to me," Mr Taylor said about the process of giving plasma, which he began doing during the Covid-19 pandemic. "I don't feel anything when I'm actually doing a donation ... because doing plasma, I'm not actually losing any of my cells. "So as far as energy levels and things like that, I'm actually pretty good. So it's actually a very easy thing to do." He was aware he was donating his plasma to Naseby publican Adrian Hood, who is receiving treatment for non-Hodgkin's lymphoma and needed plasma products, but yesterday was the first time the pair had met. "It's just been awesome that there are people out there like Terry — the treatment, the energy that these people put out on a day-by-day basis, it's just phenomenal. I mean, it's a real gift." Mr Hood said his visits to Dunedin and occasionally Christchurch for treatment had become increasingly frequent. Cancer patient Adrian Hood looks on as Terry Taylor makes his 50th plasma donation. Also enjoying the occasion are (second from left) New Zealand Blood Service haematologist Annette Neylon and Mr Hood's partner, Jan Rutherford. PHOTO: STEPHEN JAQUIERY He was diagnosed with non-Hodgkin's lymphoma on Christmas Eve. "I'm 62, and just as I thought my life was winding down, it started to wind up. "I'm still getting my head around my new itinerary. It's obviously been a shock for my family and everyone." Mr Taylor said he knew of the benefits of giving plasma, but actually seeing who it benefited made yesterday immensely satisfying. "I think that's a really important aspect. We often forget about the other side of healthcare." New Zealand Blood Service haematologist Annette Neylon said there was an increasing need for donations — about 5000 per week in New Zealand across whole blood and plasma. "I think it's a lot easier than some people expect. Come along, we need at least 4000 new donors in the coming years — about 20% of our donors are over the age of 65. "So we need to make sure that the younger generation are also becoming blood donors as we go forward as well."
NZ Herald
2 days ago
- NZ Herald
NZX50 lifts 0.5%, Metroglass cracks and Eroad climbs
'New Zealand dairy is still in demand, which is good and bad for them. It's an input cost for the consumer business, but generally good for farmers and their cooperative members.' Infratil continued its solid run since mid-June, gaining 1.77% to $7.67. The infrastructure investor traded at under $10 as recently as April. Takeovers, small caps Metro Performance Glass shares fell 20% to 4 cents after the glass supplier unveiled its plan to shore up its finances and secure new banking facilities. The company has agreed a deal with Amari Metals for the latter to take a 51% stake in the company following its proposed recapitalisation. The equity raise combines an $8.9m pro-rata rights offer with an additional placement to Amari Metals of up to $15m. Both tranches are priced at 3 cents per share (cps). Metroglass said an independent report by Grant Samuel concluded there were 'no viable alternatives'. Also on the takeover front, Vital's board urged investors to accept Tait Communication's takeover offer, warning the deal could collapse if the 90% minimum acceptance condition is not met before the mid-September deadline. In June, Tait Communications, a Christchurch-based critical communications systems provider, made a formal offer to purchase NZX-listed Vital for 45cps. On Friday, the board reiterated its unanimous recommendation, urging shareholders to accept 'without delay'. Vital shares fell 3.3% to 44c, having traded above the offer price towards the end of last week. Eroad continued its run from last week, rising 7.18% to $2.09 on Monday. The share price for telematics and fleet management rose to a three-year high after the Government announced it would transition the light vehicle fleet to road user charges. Earnings season Robertshawe noted that due to continuous disclosure requirements, companies had already confessed their sins in June and July. Subsequently, he said markets were unlikely to be too surprised by earnings reports. 'People will be looking for the quality of results. Are there abnormals? Are there provision releases? Are there one-off sale processes? That will be the key. 'And then obviously the reporting on trading since the balance date, and what does trading look like for the first half of the 2026 financial year? Vista Group, which reports its half-year results on Thursday, would be the most interesting stock to watch this week, he said. 'They hinted at a slight slowdown in uptake and migration to their new product, but it feels almost like they don't have the resources to go faster, as they've tried to hit free cash flow break-even. 'There could be an interesting announcement where they say they're going to push the company back into short-term cash flow deficits because they want to accelerate the growth to the new revenue model.' Vista traded flat at $3.50 on volumes worth nearly $1.5m.
Techday NZ
2 days ago
- Techday NZ
Exclusive: SAP's Ashley McGibbon on AI, data and the future of partner innovation
SAP is betting big on artificial intelligence, but only if it's built on a solid foundation of accurate data. Speaking to TechDay at the SAP NOW AI Tour in Melbourne, Chief Partner Officer for SAP Australia and New Zealand, Ashley McGibbon, said partners in the region were "pivoting to meet fast-growing demand for AI solutions". "In ANZ we have about 800 partners – from those building applications, to services partners, to those helping us sell and position our cloud solutions," she said. "The focus is no longer just on go-live. It's about continuous adoption." This vision is captured in SAP's "flywheel" model, which combines applications, data and AI to build momentum for ongoing innovation. Introduced this year, the concept draws on the physics principle where connected components generate increasing energy. For McGibbon, it's not just about clever technology – it's about feeding AI the right inputs. "We run mission-critical business processes, and those processes hold a treasure trove of business-critical data," she explained. "Our Business Data Cloud allows customers to harmonise SAP and non-SAP data, structured and unstructured, to feed AI with accurate business data." Without that accuracy, she warned, AI can go badly wrong. "If they can't trust the data feeding the AI, then the decisions will ultimately be wrong," she said. "It's far easier to achieve a harmonised platform with Business Data Cloud." McGibbon said SAP values partners who work quickly and with purpose, adopting a "minimum viable product" mindset to deliver rapid returns for customers. She noted a surge of AI interest at board level, with directors eager to explore how it can boost productivity, in line with the Australian Government's focus on data-driven efficiency. The response to Business Data Cloud since its February launch has been "the most reception to a new product" SAP has ever had in the region. The momentum is already visible in real-world deployments. SA Power Networks has built a generative AI app on SAP's Business Technology Platform that delivers mobile repair instructions directly to technicians in the field, saving the utility a million Australian dollars in its first year. Beverage company Lion built an app in just 10 days, a sign of how diverse industries are embracing AI. McGibbon pointed to Deloitte's recent CFO study, which found 80 per cent of CFOs in APAC prioritise automation through AI. "Everybody's talking about it," she said. For partners still making the shift to cloud and AI, McGibbon said enablement is key. SAP has opened its AI demo systems to partners, rolled out a new business AI certification, and launched "Joule for consultants" to speed up software build and implementation. She's also watching the market evolve through moves like DyFlex's acquisition of Bluetree, which expands into New Zealand and strengthens analytics capability. "It's a combination of a cloud-native partner with an analytics partner," she said. "I think they will bring AI strategy to life across all their existing cloud customers." Central to McGibbon's message is a change in how success is measured. "In the past we celebrated go-lives. For me, it's now go-begin – get the platform right, then continue that cycle of innovation," she said. Quarterly cloud updates mean partners must be ready to help customers adopt new capabilities quickly. "That's how we make the flywheel spin." She believes AI is also prompting customers to rethink design from the outset. "Customers are demanding we look at AI as part of the design, not just copying what was done before," she said. "This is the time to do it better." Early wins, she added, are often found in human capital management. "In SuccessFactors, you can use Joule to write your performance review and it makes you sound amazing," she said. "There's a lot of low-hanging fruit for existing customers." Her advice to organisations exploring AI in the SAP ecosystem is simple but firm: talk to your partners, identify the easy use cases, and above all, get your data strategy right. "You have to get that right first," she said. "Once you've done that, the world is your oyster."
